Atlas Trials

Addition of Chidamide to the Combination Treatment of Decitabine Plus Camrelizumab in Combination Treatment Resistant/Relapsed Patients With Classical Hodgkin Lymphoma

Clinical trial NCT04233294 · UNKNOWN

Trial details

NCT number
NCT04233294
Sponsor
Chinese PLA General Hospital
Status
UNKNOWN
Phase
Phase 2
Study type
INTERVENTIONAL
Hodgkin Lymphoma
Start date
2020-02-02
Primary completion
2024-02-01
Enrollment
100

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.